Peptidomimetics
6 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- ABT-510ABT-510 is an investigational synthetic nonapeptide that mimics the anti‑angiogenic protein thrombospondin‑1. It has been evaluated in early‑phase clinical studies for several solid tumours, including glioblastoma, metastatic melanoma, renal cell carcinoma and soft‑tissue sarcoma, as well as in veterinary trials of canine sarcoma. The peptide is intended to inhibit tumour blood‑vessel formation and thereby slow cancer growth.
- BelnacasanBelnacasan (also known as VX‑765 or ICE inhibitor VX‑765) is an investigational, orally administered peptidomimetic that selectively inhibits caspase‑1. It is being explored in pre‑clinical models for conditions driven by inflammasome‑mediated inflammation, such as abdominal aortic aneurysm, sepsis‑induced lung injury, viral neuroinflammation, and as a potential anti‑epileptic anti‑inflammatory agent.
- BirinapantBirinapant (TL32711) is a bivalent peptidomimetic SMAC mimetic that antagonizes inhibitor of apoptosis proteins (IAPs). It is being investigated as an intravenous anticancer agent for solid tumours, including ovarian, head‑and‑neck, and various refractory malignancies. The drug is not approved for any indication and remains in early‑phase clinical research.
- RotigaptideRotigaptide is a synthetic, investigational peptide that modifies cardiac gap junctions to improve intercellular electrical coupling. Developed as an anti‑arrhythmic agent, it is being studied for prevention of ventricular and atrial tachyarrhythmias and for protection against ischaemia‑reperfusion injury during myocardial infarction.
- SF1126SF1126 is an investigational, cRGD‑PEGylated peptidomimetic pro‑drug that delivers the pan‑phosphoinositide‑3‑kinase (PI3K) inhibitor LY294002. It targets the PI3K/Akt/mTOR signaling axis and, in later studies, also inhibits the bromodomain protein BRD4. Developed for oncology, it has been examined in early‑phase trials for solid tumours, B‑cell malignancies and multiple myeloma, and in pre‑clinical models of colorectal cancer, neuroblastoma, and Ewing sarcoma.
- SolnatideSolnatide (also known as AP301 or TIP peptide) is an investigational synthetic 17‑amino‑acid peptide that mimics the lectin‑like domain of tumor necrosis factor. It is being studied for inhaled use in patients with moderate‑to‑severe acute respiratory distress syndrome (ARDS) to accelerate clearance of pulmonary permeability edema.